Ameriprise’s ALX Oncology ALXO Stock Holding History

Ameriprise’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-652,897	Closed	-$1.19M	–	4077
2025 Q3	$1.19M	Buy	+652,897	New	+$565K	﹤0.01%	3267
2024 Q2	–	Sell	-11,535	Closed	-$129K	–	3860
2024 Q1	$129K	Buy	+11,535	New	+$162K	﹤0.01%	3749

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Ameriprise's ALXO Position: Q4 2025 in Review

Ameriprise sold out of ALX Oncology (ALXO) in Q4 2025, closing a stake of 652,897 shares — an estimated $1.19M sold.

Ameriprise first reported a position in ALXO in Q1 2024 and held it in 2 quarters. The position peaked at $1.19M in Q3 2025. 57 funds tracked by Wall St. Rank hold ALXO as of Q4 2025.

Ameriprise reported no remaining ALX Oncology position as of Q4 2025 after selling out during the quarter.
Ameriprise sold 652,897 ALX Oncology shares in Q4 2025, an estimated $1.19M.
Ameriprise first reported a position in ALX Oncology in Q1 2024 and held it in 2 quarters.
Ameriprise's ALX Oncology position peaked at $1.19M in Q3 2025.
57 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2025.

Based on Ameriprise's 13F filing for Q4 2025, filed 17 Feb 2026.